Last updated: August 1, 2026
Catapres-TTS-2 is the 0.2 mg/day transdermal clonidine hydrochloride patch, indicated for hypertension. Its clinical development is complete, regulatory exclusivity has expired, and the product competes with generic clonidine patches and oral antihypertensive therapies. No active branded clinical-development program or meaningful patent barrier supports market exclusivity. Future demand is likely to remain concentrated in patients who require once-weekly transdermal delivery, have adherence problems, or cannot tolerate standard oral treatment.
What is Catapres-TTS-2?
Catapres-TTS-2 delivers approximately 0.2 mg of clonidine per day through the skin for seven days. The patch is one of three historical strengths:
| Product |
Nominal delivery rate |
Weekly clonidine content |
| Catapres-TTS-1 |
0.1 mg/day |
2.5 mg |
| Catapres-TTS-2 |
0.2 mg/day |
5.0 mg |
| Catapres-TTS-3 |
0.3 mg/day |
7.5 mg |
The active ingredient, clonidine hydrochloride, is a centrally acting alpha-2 adrenergic agonist. It reduces sympathetic outflow and lowers blood pressure. The FDA label warns about hypotension, bradycardia, sedation, dry mouth, contact dermatitis and rebound hypertension after abrupt discontinuation. Patients generally transition from oral clonidine to the patch over two to three days because the transdermal system reaches therapeutic concentrations gradually (FDA, 2020).
Catapres-TTS-2 is a transdermal delivery system rather than a new chemical entity. Its commercial differentiation depends on weekly dosing, patch adhesion, tolerability and supply reliability.
What is the FDA status of Catapres-TTS-2?
Catapres-TTS was approved in the United States under NDA 018813 for hypertension. The product is an approved prescription transdermal clonidine system, not a biologic and not an over-the-counter medicine. The FDA-approved indication is hypertension, either alone or with other antihypertensive agents (FDA, 2020).
The FDA label does not establish Catapres-TTS-2 as an approved treatment for attention-deficit/hyperactivity disorder, opioid withdrawal, menopausal vasomotor symptoms or pain. Clonidine is used in some of those settings, but such uses are generally off-label unless supported by a separate approved product and indication.
Is Catapres-TTS-2 still marketed?
The Catapres-TTS brand has had limited commercial visibility compared with generic clonidine transdermal systems. U.S. pharmacy availability can vary by wholesaler, manufacturer and strength. Product status should be checked against current FDA drug listings and commercial distribution records rather than assumed from historical brand references.
Generic clonidine transdermal products may be listed under the active ingredient and dosage form rather than under the Catapres-TTS brand. This distinction matters for reimbursement, substitution and market-share analysis.
Are there current clinical trials for Catapres-TTS-2?
Catapres-TTS-2 has no apparent active late-stage clinical program. Its pivotal clinical development occurred before current ClinicalTrials.gov registration practices became standard. Current research involving clonidine generally concerns other formulations, indications or comparators rather than Catapres-TTS-2 as a branded product.
A ClinicalTrials.gov search for Catapres-TTS and transdermal clonidine is relevant for identifying newly registered studies, but the product’s clinical risk is regulatory and commercial rather than trial-driven. The principal evidence base consists of historical hypertension studies, pharmacokinetic work and postmarketing safety information (ClinicalTrials.gov, 2025).
What clinical evidence supports the patch?
The transdermal system provides sustained clonidine exposure over approximately seven days. Compared with immediate-release oral clonidine, the patch reduces dosing frequency and can reduce peak-to-trough fluctuations. The pharmacologic tradeoff is slower onset and slower offset.
Important clinical limitations include:
- Sedation and fatigue.
- Dry mouth and constipation.
- Skin irritation or allergic contact dermatitis.
- Bradycardia and hypotension.
- Rebound hypertension after abrupt withdrawal.
- Reduced suitability for patients requiring rapid dose adjustment.
The patch is most commercially defensible when adherence or oral administration is a problem. It is less attractive when clinicians want rapid titration or when the patient has sensitivity to adhesive systems.
What patents protect Catapres-TTS-2?
The original Catapres-TTS patent estate is effectively expired in the United States. The product launched decades ago, and any core composition, reservoir, adhesive or delivery patents associated with the original system would have reached the end of their statutory terms.
| IP category |
Current commercial significance |
| Clonidine compound patents |
Expired |
| Original transdermal-system patents |
Expired or no longer commercially exclusionary |
| Catapres-TTS-2 strength-specific protection |
No meaningful remaining exclusivity identified |
| Generic formulation patents |
May protect individual manufacturers’ processes or excipients, but do not block the clonidine patch category |
| Trademarks |
May protect branding, not the active ingredient or clinical market |
The relevant U.S. regulatory listing is the Orange Book entry for NDA 018813 and associated abbreviated new drug applications. Orange Book status should be reviewed by strength and dosage form because the presence of an ANDA does not guarantee continuous commercial supply (FDA, 2025a).
Does Catapres-TTS-2 have remaining market exclusivity?
No meaningful FDA new-drug exclusivity remains. Catapres-TTS-2 is exposed to generic substitution and does not benefit from orphan-drug, pediatric, new chemical entity or qualified infectious-disease exclusivity.
Patent term restoration is also not commercially relevant to this mature product. Any historical regulatory exclusivity period has expired.
Are there Paragraph IV challenges to Catapres-TTS-2?
Paragraph IV litigation risk is limited because the underlying product and delivery technology are old. Generic clonidine transdermal entrants could historically have challenged listed patents through ANDA certifications, but the commercial issue today is supply, substitution and manufacturing economics rather than a live branded patent dispute.
No major current Paragraph IV campaign or active Hatch-Waxman litigation materially affecting Catapres-TTS-2 is evident in the public record reviewed for this analysis. The absence of litigation does not prevent future ANDA activity, but it reduces the likelihood that a patent settlement will control generic entry.
What is the Orange Book status of Catapres-TTS-2?
Catapres-TTS is associated with the FDA-approved clonidine transdermal product under NDA 018813. The Orange Book may list approved generic applications and therapeutic-equivalence information by product strength. The practical questions for market access are:
- Whether a generic 0.2 mg/day patch has an active approval.
- Whether the product is currently listed as marketed.
- Whether the approved generic is therapeutically equivalent.
- Whether multiple manufacturers can supply the patch.
- Whether state substitution rules apply to the specific product code.
An Orange Book listing confirms regulatory approval but does not confirm current inventory or commercial availability. Drug-shortage databases and wholesaler data are necessary for supply analysis (FDA, 2025b).
Which companies challenge Catapres-TTS-2 commercially?
Generic manufacturers, rather than branded innovators, represent the main competitive threat. Historical U.S. suppliers of clonidine transdermal systems have included companies such as Mylan and Actavis-related businesses, although manufacturer participation and marketing status can change over time.
The competitive set includes:
| Competitor |
Competitive relationship |
| Generic clonidine patch |
Direct product substitute |
| Oral clonidine tablets |
Lower-cost alternative, more frequent dosing |
| Clonidine extended-release tablets |
Alternative clonidine formulation, mainly used in ADHD-related treatment |
| Guanfacine |
Oral alpha-2 agonist alternative |
| ACE inhibitors and ARBs |
First-line hypertension competitors |
| Calcium-channel blockers |
First-line hypertension competitors |
| Beta blockers and diuretics |
Selective or combination-treatment alternatives |
Major hypertension guidelines generally favor thiazide-type diuretics, ACE inhibitors, ARBs and calcium-channel blockers over centrally acting agents for initial treatment. That guideline position limits the addressable hypertension market for clonidine patches (Whelton et al., 2018).
What formulations are protected by Catapres-TTS-2?
The commercially relevant formulation is the seven-day transdermal delivery system. Protection historically centered on the patch architecture, adhesive layer, drug reservoir or matrix and controlled release of clonidine.
There is no current evidence that Catapres-TTS-2 retains enforceable formulation exclusivity capable of blocking generic development. A manufacturer could still obtain patents on a redesigned adhesive, backing layer, manufacturing process or stability profile. Those patents would normally protect the specific improvement rather than the entire clonidine transdermal market.
Manufacturing remains a practical barrier. Transdermal patches require control of drug loading, adhesive uniformity, crystallization, liner removal, adhesion, skin permeation and packaging stability. These requirements can reduce the number of reliable suppliers even when legal exclusivity has ended.
What patent litigation and settlements affect Catapres-TTS-2?
No current patent litigation or settlement agreement appears to control U.S. entry for Catapres-TTS-2. The product’s age and generic availability reduce the strategic value of a late-stage patent settlement.
Potential disputes would more likely concern:
- Product-specific ANDA approval.
- Therapeutic equivalence.
- Adhesive performance.
- Manufacturing deviations.
- Trade dress or trademark use.
- Supply and contract-manufacturing agreements.
Trademark disputes would not restore exclusivity over clonidine or the transdermal dosage form.
Does Catapres-TTS-2 face biosimilar risk?
No. Catapres-TTS-2 is a small-molecule drug-device combination product, not a biologic. It is exposed to generic drug competition and formulation substitution, not biosimilar competition under the Public Health Service Act.
The relevant regulatory pathway is an ANDA or, in some cases, a suitability petition or alternative pathway depending on the product’s formulation and reference-product status. FDA requirements focus on pharmaceutical equivalence, bioequivalence, quality and performance of the transdermal system.
How large is the Catapres-TTS-2 market?
Catapres-TTS-2 is a niche product within the global antihypertensive market. Its sales are constrained by four factors:
- Hypertension treatment has shifted toward first-line oral therapies.
- Clonidine is often reserved for selected patients because of central nervous system and withdrawal effects.
- Generic pricing limits revenue per prescription.
- Weekly patches compete against inexpensive oral tablets.
The product retains demand in several segments:
- Patients with poor adherence to daily oral therapy.
- Patients with difficulty swallowing.
- Patients requiring clonidine but unable to maintain oral dosing.
- Patients receiving palliative or complex medication management.
- Selected patients with autonomic symptoms or withdrawal-related treatment needs.
Product-specific global revenue estimates are not consistently disclosed by manufacturers. Market projections should therefore be based on prescription volume, average selling price, generic share, manufacturer count and patch availability rather than on historical Catapres brand revenue.
What is the market projection for Catapres-TTS-2?
The base-case outlook is a mature, declining-to-stable niche market rather than a growth market.
| Period |
Expected market condition |
| 2025-2027 |
Generic-led demand, intermittent supply variability, limited branded investment |
| 2028-2030 |
Continued substitution by oral therapies and generic patches |
| 2031 onward |
Persistent residual demand, with commercial viability dependent on supplier reliability |
The most likely revenue pattern is flat to modestly declining volume with low pricing. A temporary increase in sales can occur if a competing patch manufacturer exits or if oral clonidine supply becomes constrained. Such gains would reflect channel disruption rather than durable clinical expansion.
The strongest commercial opportunity is not a premium branded relaunch. It is dependable generic supply, improved adhesive performance, simplified packaging, hospital contracting and distribution to long-term-care and specialty pharmacies.
What generic launch scenarios exist for Catapres-TTS-2?
Scenario 1: Stable generic supply
Multiple approved suppliers maintain inventory. Prices remain low, substitution is routine and the brand has limited negotiating leverage.
Scenario 2: Single-supplier concentration
One or two manufacturers remain active. A manufacturing interruption creates shortages, temporary price increases and increased demand for alternative clonidine formulations.
Scenario 3: Brand re-entry
A branded manufacturer could relaunch Catapres-TTS-2 through a specialty or contract-commercialization model. Success would require a clear supply, adherence or device-performance advantage because patent exclusivity would not support premium pricing.
Scenario 4: Formulation replacement
Patients migrate to oral clonidine extended-release, guanfacine or other antihypertensive therapies. This is the long-term structural risk.
How strong is the Catapres-TTS-2 patent estate?
The patent estate is weak as a source of market exclusion. Its commercial strength lies in historical clinical familiarity, regulatory approval and physician recognition, not in surviving patent claims.
| Factor |
Assessment |
| Core active ingredient |
Weak, expired |
| Original transdermal technology |
Weak, aged estate |
| FDA exclusivity |
Expired |
| Generic entry barrier |
Low to moderate, driven by manufacturing |
| Device and adhesive complexity |
Moderate operational barrier |
| Litigation leverage |
Low |
| Geographic exclusivity |
Limited |
| Brand recognition |
Moderate but declining |
| Revenue protection |
Low |
What is the geographic coverage of Catapres-TTS-2?
Clonidine transdermal products have been marketed in several countries, but brand status, approved strengths and reimbursement differ by jurisdiction. U.S. commercial exposure is governed by FDA approval, Orange Book listings, state substitution rules and distributor inventory.
In Europe and other markets, the product may face different requirements for transdermal equivalence, pharmacokinetic bridging, device performance and local pricing. Patent expiry generally means that geographic opportunity depends on registration and supply execution rather than on remaining exclusivity.
Key Takeaways
- Catapres-TTS-2 is the 0.2 mg/day, seven-day clonidine transdermal patch.
- Its FDA-approved use is hypertension.
- Clinical development is mature, with no apparent active branded development program.
- Core patent and regulatory exclusivity have expired.
- No meaningful current Paragraph IV litigation or settlement appears to control entry.
- The product is not subject to biosimilar competition.
- Generic clonidine patches and oral antihypertensives define the competitive market.
- Demand is likely to remain niche and stable to declining.
- Manufacturing, adhesive quality and supply continuity are more important than patent protection.
- The best commercial opportunity is reliable generic supply or a demonstrably improved patch system.
FAQs About Catapres-TTS-2
Is Catapres-TTS-2 stronger than Catapres-TTS-1?
Yes. Catapres-TTS-2 delivers approximately 0.2 mg of clonidine per day, compared with 0.1 mg per day for Catapres-TTS-1.
How long does a Catapres-TTS-2 patch last?
The patch is designed for seven days of continuous delivery.
Can Catapres-TTS-2 be stopped suddenly?
Abrupt discontinuation can cause rebound hypertension and other withdrawal effects. Discontinuation should follow the product label and clinical supervision.
Is clonidine patch available as a generic?
Generic clonidine transdermal systems have been approved and marketed in the United States, although availability can vary by strength, manufacturer and distribution channel.
Is Catapres-TTS-2 used for ADHD?
Clonidine is used in some ADHD treatment settings, but the FDA-approved Catapres-TTS-2 indication is hypertension. Use for ADHD should not be treated as an approved indication for the patch.
References
ClinicalTrials.gov. (2025). Search results for Catapres-TTS and transdermal clonidine. U.S. National Library of Medicine. https://clinicaltrials.gov/search
U.S. Food and Drug Administration. (2020). Catapres-TTS: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/018813s027lbl.pdf
U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2025b). FDA drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
